Project Name: Barts NET Service Expansion

Project Summary: 

The CW Partner and Novartis are launching a Collaborative Working Project to address critical capacity and equity challenges within the CW Partners Endocrinology Neuroendocrine Tumor (NET) Service. This initiative responds to a significant rise in NET referrals, growing patient complexity, and regional disparities in care across North East London (NEL). The project aims to enhance patient outcomes, improve staff and patient experience, and position Barts as a future European Neuroendocrine Tumor Society (ENETS) Centre of Excellence.

The expected outcomes of this CWP are:

  1. Improve patient outcomes and experience by reducing time between referral, diagnosis and subsequent treatment in line with referral to treatment targets
  2. Increased number of patients able to access the NET service reducing health inequalities faced by the patients of North East London (NEL)
  3. Improve staff and patient experience
  4. Improved clinical follow-up processes; leading to improved patient experience and better patient access to clinical review

The project is structured around 14 milestones, including recruitment, baseline data collection, regular activity reporting, and staff and patient satisfaction surveys.

Expected Benefits: 

Patient Benefits

  • Improved access to evidence-based treatment bringing better equity of care to the patients of NEL
  • Enhanced and more equitable experience for patients and their carers from North East London, reducing travel and improving access to locally available specialist. This will be achieved by strengthening MDT & ensuring more North East London patients who are currently referred elsewhere (or not at all) can access Barts MDT
  • Improved patient information and education by establishing dedicated CNS capacity to provide information & education to NETs patients on their disease and medical management

Barts Health NHS Trust Benefits

  • Increase clinic capacity to enable local support for greater patient numbers
  • Improved communication of decision making and clarity of pathway, leading to better and more timely patient care
  • Improved staff experience of working in the NETs service enhancing the patient experience and potentially leading to longer staff retention
  • Efficiencies around long-term FU of patients. This will allow for a review and optimisation of staff time over the medium term, with potential for increased capacity for patient care and improve patient experience as they only attend the hospital when they need tp
  • Developing as Centre of Excellence for NETs in NEL

Novartis Benefits

  • Expected increase in access for Nuclear Medicine Therapies (which may include Novartis Therapies)
  • Strengthened partnerships with healthcare organisations through ethical, transparent, and collaborative engagement.
  • Enhanced reputation as a trusted partner in the delivery of advanced cancer therapies.
  • Deeper insights into patient and healthcare professional needs, enabling more responsive and tailored support.
  • Shared learning and best practice development, including the role of specialist staff in optimising care pathways.

 

Start Date & Duration: 

Start date: October 2025. 

Duration: 33 Months

FA-11523735 | September 2025